HK1211476A1 - Combination of pi3k inhibitor and c-met inhibitor pi3k c-met - Google Patents

Combination of pi3k inhibitor and c-met inhibitor pi3k c-met

Info

Publication number
HK1211476A1
HK1211476A1 HK15112283.4A HK15112283A HK1211476A1 HK 1211476 A1 HK1211476 A1 HK 1211476A1 HK 15112283 A HK15112283 A HK 15112283A HK 1211476 A1 HK1211476 A1 HK 1211476A1
Authority
HK
Hong Kong
Prior art keywords
met
pi3k
inhibitor
combination
pi3k inhibitor
Prior art date
Application number
HK15112283.4A
Other languages
English (en)
Chinese (zh)
Inventor
Giordano Caponigro
Xizhong Huang
Joseph Lehar
hui-qin Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1211476A1 publication Critical patent/HK1211476A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15112283.4A 2012-08-16 2015-12-14 Combination of pi3k inhibitor and c-met inhibitor pi3k c-met HK1211476A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261683790P 2012-08-16 2012-08-16
PCT/US2013/054848 WO2014028566A1 (en) 2012-08-16 2013-08-14 Combination of pi3k inhibitor and c-met inhibitor

Publications (1)

Publication Number Publication Date
HK1211476A1 true HK1211476A1 (en) 2016-05-27

Family

ID=49004065

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15112283.4A HK1211476A1 (en) 2012-08-16 2015-12-14 Combination of pi3k inhibitor and c-met inhibitor pi3k c-met

Country Status (14)

Country Link
US (5) US20150216870A1 (es)
EP (1) EP2885003B1 (es)
JP (3) JP2015529194A (es)
KR (2) KR102245985B1 (es)
CN (1) CN105050623B (es)
AU (4) AU2013302702A1 (es)
BR (1) BR112015002528A2 (es)
CA (1) CA2879704A1 (es)
ES (1) ES2901712T3 (es)
HK (1) HK1211476A1 (es)
IN (1) IN2015DN00528A (es)
MX (1) MX369518B (es)
RU (1) RU2705095C2 (es)
WO (1) WO2014028566A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013046136A1 (en) 2011-09-27 2013-04-04 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
RU2660354C2 (ru) 2012-04-03 2018-07-05 Новартис Аг Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
AP2015008707A0 (en) 2013-03-14 2015-09-30 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
WO2014203152A1 (en) * 2013-06-18 2014-12-24 Novartis Ag Pharmaceutical combinations
JP6770946B2 (ja) 2014-07-25 2020-10-21 ノバルティス アーゲー ２−フルオロ−ｎ−メチル−４−［７−（キノリン−６−イルメチル）イミダゾ［１，２−ｂ］［１，２，４］トリアジン−２−イル］ベンズアミドの錠剤
CN108367003B (zh) 2014-12-12 2022-01-21 麻省总医院 乳腺癌脑转移的治疗
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AU2007323725B2 (en) * 2006-11-22 2014-02-20 Incyte Holdings Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
CN104758288A (zh) * 2007-02-20 2015-07-08 诺华股份有限公司 作为脂质激酶和mTOR双重抑制剂的咪唑并喹啉类
KR20100131446A (ko) * 2008-03-05 2010-12-15 노파르티스 아게 Ｅｇｆｒ 의존성 질환 또는 ｅｇｆｒ 족 구성원을 표적으로 하는 작용제에 대한 내성을 획득한 질환의 치료를 위한 피리미딘 유도체의 용도
MY187131A (en) * 2008-05-21 2021-09-02 Incyte Corp Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
MX2011000440A (es) * 2008-07-11 2011-02-24 Novartis Ag Combinacion de (a) un inhibidor de fosfoinositido 3-cinasa y (b) un modulador de la ruta de ras/raf/mek.
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US20100267742A1 (en) * 2009-04-17 2010-10-21 Rush University Medical Center Combination targeted therapy for lung cancer
AR083267A1 (es) * 2010-10-04 2013-02-13 Novartis Ag Combinaciones farmaceuticas
WO2012062694A1 (en) * 2010-11-08 2012-05-18 Novartis Ag Use of 2-carboxamide cycloamino urea derivatives in the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members

Also Published As

Publication number Publication date
US20190350935A1 (en) 2019-11-21
US20200253980A1 (en) 2020-08-13
RU2705095C2 (ru) 2019-11-05
CA2879704A1 (en) 2014-02-20
AU2019226212A1 (en) 2019-09-26
CN105050623B (zh) 2018-06-12
MX2015002005A (es) 2015-10-08
IN2015DN00528A (es) 2015-06-26
EP2885003B1 (en) 2021-09-29
CN105050623A (zh) 2015-11-11
AU2019226212B2 (en) 2020-05-14
JP2020079243A (ja) 2020-05-28
KR20210049187A (ko) 2021-05-04
BR112015002528A2 (pt) 2018-05-22
AU2018201725A1 (en) 2018-04-05
JP2018035188A (ja) 2018-03-08
JP6644042B2 (ja) 2020-02-12
ES2901712T3 (es) 2022-03-23
JP2015529194A (ja) 2015-10-05
EP2885003A1 (en) 2015-06-24
US20150216870A1 (en) 2015-08-06
AU2016238903A1 (en) 2016-10-27
JP6970217B2 (ja) 2021-11-24
US20190083500A1 (en) 2019-03-21
KR20150043328A (ko) 2015-04-22
KR102245985B1 (ko) 2021-04-30
AU2013302702A1 (en) 2015-02-19
US20220280523A1 (en) 2022-09-08
WO2014028566A1 (en) 2014-02-20
RU2015108755A (ru) 2016-10-10
MX369518B (es) 2019-11-11

Similar Documents

Publication Publication Date Title
HRP20181628T1 (hr) Spojevi i postupci za njihovu upotrebu
HRP20180953T1 (hr) Supstituirani 3-haloalilaminski inhibitori za ssao i njihove uporabe
HK1208439A1 (en) 5-azaindazole compounds and methods of use 5-
IL237849B (en) ret suppressors and their uses
IL235436A0 (en) Anti-pcsk9 preparations and their use
EP2836218A4 (en) PROBIOTIC COMPOSITIONS AND METHODS OF USE
SG10202003090VA (en) PI3K δ INHIBITOR
HK1211476A1 (en) Combination of pi3k inhibitor and c-met inhibitor pi3k c-met
HK1202112A1 (en) Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
HK1212251A1 (en) Topical compositions and methods of use
ZA201406082B (en) Use of ccr3-inhibitors
EP2906041A4 (en) COMPOSITIONS AND METHODS OF USING INAPPETENCE COMPOUND
HK1201066A1 (en) Pyranopyridone inhibitors of tankyrase
EP2939668A4 (en) PDK4 INHIBITOR AND USE THEREOF
ZA201408128B (en) Etract of greyia radlkoferi and use thereof
HK1210464A1 (en) Pi3k and/or mtor inhibitor pi3k / mtor
EP2841164A4 (en) COMPOSITIONS AND USE PROCEDURES FOR THE SKIN